Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Ther Adv Chronic Dis ; 13: 20406223221117449, 2022.
Article in English | MEDLINE | ID: mdl-36003287

ABSTRACT

Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease. Not only genetics, but the intestinal environment affected by gut microbiota is also the key to pathogenesis. Besides the occurrence of diabetes, gut microbiota dysbiosis may also contribute to the development of diabetes-related complications. Fecal microbiota transplantation (FMT) is an emerging technique that had shown its potential as a treatment for metabolic disease. Here, we report the first case of T1DM with malnutrition and gastrointestinal symptoms treated with FMT. A 24-year-old T1DM patient suffered from poor blood glucose control, recurrent nausea and vomiting, severe malnutrition, and intractable constipation after insulin treatment. The clinical response of the patients after FMT was well, especially nausea and vomiting were significantly relieved. In addition, constipation, nutritional status, and blood glucose control (fasting blood glucose, HbA1c) gradually improved. A degree of similarity was found in gut microbiota composition between the patient and healthy donor after FMT while it was totally different before the treatment. Furthermore, pathway function analysis of MetaCYC database implies that the potential mechanism of the response of FMT may be driven by specific bacteria involved in several metabolic pathways that need further exploration. To sum up, we believe that the reconstruction of intestinal flora by FMT may be a new choice for the treatment of T1DM patients with malnutrition.

2.
Aging (Albany NY) ; 13(7): 9522-9541, 2021 02 03.
Article in English | MEDLINE | ID: mdl-33539323

ABSTRACT

Chronic cerebral hypoperfusion (CCH) may lead to the cognitive dysfunction, but the underlying mechanisms are unclear. EGB761, extracted from Ginkgo biloba and as a phytomedicine widely used in the world, has been showed to have various neuroprotective roles and mechanisms, and therapeutic effects in Alzheimer's disease and other cognitive dysfunctions. However, improvements in cognitive function after CCH, following treatment with EGB761, have not been ascertained yet. In this study, we used the behavior test, electrophysiology, neurobiochemistry, and immunohistochemistry to investigate the EGB761's effect on CCH-induced cognitive dysfunction and identify its underlying mechanisms. The results showed that EGB761 ameliorates spatial cognitive dysfunction occurring after CCH. It may also improve impairment of the long-term potentiation, field excitable potential, synaptic transmission, and the transmission synchronization of neural circuit signals between the entorhinal cortex and hippocampal CA1. EGB761 may also reverse the inhibition of neural activity and the degeneration of dendritic spines and synaptic structure after CCH; it also prevents the downregulation of synaptic proteins molecules and pathways related to the formation and stability of dendritic spines structures. EGB761 may inhibit axon demyelination and ameliorate the inhibition of the mTOR signaling pathway after CCH to improve protein synthesis. In conclusion, EGB761 treatment after CCH may improve spatial cognitive function by ameliorating synaptic plasticity impairment, synapse degeneration, and axon demyelination by rectifying the inhibition of the mTOR signaling pathway.


Subject(s)
Brain Ischemia/complications , Cognitive Dysfunction/drug therapy , Ginkgo biloba , Neuronal Plasticity/drug effects , Neuroprotective Agents/therapeutic use , Plant Extracts/therapeutic use , Animals , Brain Ischemia/metabolism , Cognitive Dysfunction/etiology , Cognitive Dysfunction/metabolism , Dendritic Spines/drug effects , Dendritic Spines/metabolism , Male , Maze Learning/drug effects , Neurons/drug effects , Neurons/metabolism , Neuroprotective Agents/pharmacology , Plant Extracts/pharmacology , Rats , Rats, Sprague-Dawley , Synapses/drug effects , Synapses/metabolism
3.
Dis Markers ; 2021: 6591784, 2021.
Article in English | MEDLINE | ID: mdl-34992694

ABSTRACT

METHODS AND RESULTS: We conducted a retrospective study of 531 patients with ultrasonogram-confirmed NAFLD who underwent percutaneous coronary intervention (PCI). Then, all patients were separated into four categories by Gensini score (0, 0-9, 9-48, and ≥48) for use in ordinal logistic regression analysis to determine whether NAFLD fibrosis was associated with increased Gensini scores. Mediation analysis was used to investigate whether systemic inflammation is a mediating factor in the association between NAFLD fibrosis and CAD severity. FIB - 4 > 2.67 (OR = 5.67, 95% CI 2.59-12.38) and APRI > 1.5 (OR = 14.8, 95% CI 3.24-67.60) remained to be independent risk factors for the severity of CAD after adjusting for conventional risk factors, whereas among the inflammation markers, only neutrophils and neutrophil-to-lymphocyte ratio (NLR) were independently associated with CAD. Multivariable ordinal regression analysis suggested that increasing Gensini score (0, 0-9, 9-48, and ≥48) was associated with advanced NAFLD fibrosis. ROC curve showed that either fibrosis markers or inflammation markers, integrating with traditional risk factors, could increase the predictive capacity for determining CAD. Inflammation markers, especially neutrophils and NLR, were mediators of the relationship between NAFLD fibrosis and CAD severity. CONCLUSIONS: NAFLD patients with advanced fibrosis are at a high risk of severe coronary artery stenosis, and inflammation might mediate the association between NAFLD fibrosis and CAD severity.


Subject(s)
Coronary Artery Disease/complications , Inflammation/complications , Liver Cirrhosis/etiology , Non-alcoholic Fatty Liver Disease/complications , Aged , Coronary Artery Disease/blood , Female , Humans , Inflammation/blood , Liver Cirrhosis/blood , Lymphocytes , Male , Middle Aged , Neutrophils , Non-alcoholic Fatty Liver Disease/blood , Retrospective Studies , Severity of Illness Index
4.
Aging (Albany NY) ; 12(19): 19520-19538, 2020 Oct 11.
Article in English | MEDLINE | ID: mdl-33040050

ABSTRACT

Cognitive dysfunction caused by chronic cerebral hypoperfusion is a common underlying cause of many cognition-related neurodegenerative diseases. The mechanisms of cognitive dysfunction caused by CCH are not clear. Long non-coding RNA is involved in synaptic plasticity and cognitive function, but whether lncRNA is involved in cognitive dysfunction caused by CCH has not yet been reported. In the present study, we identified the altered lncRNAs and mRNAs by deep RNA sequencing. A total of 128 mRNAs and 91 lncRNAs were up-regulated, and 108 mRNAs and 98 lncRNAs were down-regulated. Real-time reverse transcription-polymerase chain reaction verified the reliability of the lncRNA and mRNA sequencing. Gene Ontology and KEGG pathway analyses showed that differentially-expressed mRNAs were related to peptide antigen binding, the extracellular space, the monocarboxylic acid transport, and tryptophan metabolism. The co-expression analysis showed that 161 differentially expressed lncRNAs were correlated with DE mRNAs. By predicting the miRNA in which both DE lncRNAs and DE mRNAs bind together, we constructed a competitive endogenous RNA network. In this lncRNAs-miRNAs-mRNAs network, 559 lncRNA-miRNA-mRNA targeted pairs were identified, including 83 lncRNAs, 67 miRNAs, and 108 mRNAs. Through GO and KEGG pathway analysis, we further analyzed and predicted the regulatory function and potential mechanism of ceRNA network regulation. Our results are helpful for understanding the pathogenesis of cognitive dysfunction caused by CCH and provide direction for further research.

5.
J Alzheimers Dis ; 66(4): 1559-1576, 2018.
Article in English | MEDLINE | ID: mdl-30452417

ABSTRACT

Chronic cerebral hypoperfusion (CCH) affects the aging population and especially patients with neurodegenerative diseases, such as Alzheimer's disease or Parkinson's disease. CCH is closely related to the cognitive dysfunction in these diseases. Glucagon-like peptide-2 receptor (GLP2R) mRNA and protein are highly expressed in the gut and in hippocampal neurons. This receptor is involved in the regulation of food intake and the control of energy balance and glucose homeostasis. The present study employed behavioral techniques, electrophysiology, western blotting, immunohistochemistry, quantitative real time polymerase chain reaction (qRT-PCR), and Golgi staining to investigate whether the expression of GLP2R changes after CCH and whether GLP2R is involved in cognitive impairment caused by CCH. Our findings show that CCH significantly decreased hippocampal GLP2R mRNA and protein levels. GLP2R upregulation could prevent CCH-induced cognitive impairment. It also improved the CCH-induced impairment of long-term potentiation and long-term depression. Additionally, GLP2R modulated after CCH the AKT-mTOR-p70S6K pathway in the hippocampus. Moreover, an upregulation of the GLP2R increased the neurogenesis in the dentate gyrus, neuronal activity, and density of dendritic spines and mushroom spines in hippocampal neurons. Our findings reveal the involvement of GLP2R via a modulation of the AKT-mTOR-p70S6K pathway in the mechanisms underlying CCH-induced impairments of spatial learning and memory. We suggest that the GLP2R and the AKT-mTOR-p70S6K pathway in the hippocampus are promising targets to treat cognition deficits in CCH.


Subject(s)
Brain Ischemia/metabolism , Glucagon-Like Peptide-2 Receptor/metabolism , Hippocampus/metabolism , Spatial Learning/physiology , Spatial Memory/physiology , Animals , Brain Ischemia/physiopathology , Dendritic Spines/metabolism , Disease Models, Animal , Male , Neuronal Plasticity/physiology , Neurons/metabolism , Phosphorylation , Proto-Oncogene Proteins c-akt/metabolism , Rats , Rats, Sprague-Dawley , Signal Transduction/physiology , TOR Serine-Threonine Kinases/metabolism , Up-Regulation
6.
Spine J ; 16(10): e649-e650, 2016 Oct.
Article in English | MEDLINE | ID: mdl-26928879
7.
Neurosci Lett ; 422(2): 87-90, 2007 Jul 11.
Article in English | MEDLINE | ID: mdl-17630209

ABSTRACT

In the present study, we investigated the effect of mild hypothermia on infarct volume, angiogenesis and brain-derived neurotrophic factor (BDNF) level after stroke. After permanent middle cerebral artery occlusion, mild hypothermia was induced immediately and maintained for 24h. 2,3,5-Triphenyltetrazolium chloride (TTC) staining, laser scanning confocal microscopy (LSCM) and ELISA were performed to assay infarct volume, angiogenesis and BDNF level in the ischemic boundary zone (IBZ), respectively. Compared with normothermic group, mild hypothermia reduced total infarct volume and increased endogenous BDNF level. And the microvessel diameter, the number of vascular branch points and the vessel surface area were significantly increased in the mild hypothermia group. These findings suggest that mild hypothermia enhances angiogenesis in ischemic brain, which might be enhanced in part via BDNF.


Subject(s)
Brain-Derived Neurotrophic Factor/metabolism , Cerebral Infarction/therapy , Hypothermia, Induced/methods , Hypoxia-Ischemia, Brain/therapy , Neovascularization, Physiologic , Animals , Brain/blood supply , Brain/metabolism , Brain/pathology , Cerebral Arteries/pathology , Cerebral Infarction/pathology , Cerebral Infarction/physiopathology , Disease Models, Animal , Hypoxia-Ischemia, Brain/pathology , Hypoxia-Ischemia, Brain/physiopathology , Infarction, Middle Cerebral Artery/pathology , Infarction, Middle Cerebral Artery/physiopathology , Infarction, Middle Cerebral Artery/therapy , Male , Microcirculation/pathology , Microscopy, Confocal , Rats , Rats, Sprague-Dawley , Tetrazolium Salts , Treatment Outcome , Up-Regulation
SELECTION OF CITATIONS
SEARCH DETAIL
...